Recently, the application of immunotherapy involving ICIs, specifically CTLA-4 and PD-1, has shown encouraging results in treating cancer, possibly due to their effect on Tregs and enhanced destruction of Teff cells [9, 16]. The gene discussed is CTLA4; the disease is cancer.